Global Kidney Fibrosis Treatment Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027
MarketResearch.biz, in its upcoming report titled, “Global Kidney Fibrosis Treatment Market Trends, Applications, Analysis, Growth, and Forecast to 2027”, offers in-depth insights, revenue details, and other vital information regarding the global kidney fibrosis treatment market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report also offers insightful and detailed information regarding the various key players operating in the global kidney fibrosis treatment market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global kidney fibrosis treatment market report has been segmented on the basis of therapeutics, end user, and region.
Kidney fibrosis or renal fibrosis is an unavoidable consequence of excessive growth of extracellular matrix that occurs virtually in all types of chronic kidney diseases. Renal scarring results in the progression of loss of renal function, which leads to end-stage renal failure or need for kidney dialysis treatment or transplant. Obesity and smoking are the main causes for increasing incidence of kidney fibrosis globally.
Among the various therapeutic treatments in the market, angiotensin converting enzyme inhibitor is more widely used and revenue from sales of these types of drugs is expected to contribute significantly to growth of the global kidney fibrosis treatment market over the forecast period. Owing to rising disposable income among consumers globally, and rising awareness about accessibility to treatments in hospitals etc., revenue from angiotensin converting enzyme inhibitor is expected to continue its dominance over the forecast period.
Other factors fueling growth of this market include increasing aging population, income saved for long term basis, growing awareness about renal fibrosis treatment, and constant technological innovation leading to development of new, more advanced, safer and effective therapies. Government initiatives for development of novel drugs is expected to fuel growth of the global kidney fibrosis treatment market. Changing lifestyle and food habits are causing a rise in kidney fibrosis patient pools, which is expected to boost demand for kidney fibrosis treatment. Mounting health awareness and health concerns among the growing populations are the factors driving growth of the target market.
Point-of-care drug delivery systems, introduction of personalized medicines, mono-therapeutic approaches or combination therapies are the opportunities expected for growth of kidney fibrosis treatment market. However, high cost involved and failure of treatments are some factors restraining growth of the global kidney fibrosis treatment market to a certain extent. This is a trend expected to continue over the forecast period.
North America dominates the global kidney fibrosis treatment market in terms of revenue share, followed by the market in Europe due to large and increasing aging patient pool and improving health facilities globally. Asia Pacific is projected to be the fastest growing market over the forecast period due to increasing medical expenditure, rising medical treatment, and rise in disposable income.
Global Kidney Fibrosis Treatment Market Segmentation:
Segmentation on the basis of therapeutic:
- Angiotensin converting enzyme inhibitors
- Renin inhibitors
- Angiotensin II receptor blockers
- Vasopeptidase inhibitors
Segmentation on the basis of end user:
- Home based treatment
- North America
- Asia Pacific
- Latin America
- Middle East & Africa.
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Hoffmann-La Roche Ltd
- Pfizer, Inc.
- La Jolla Pharmaceutical Company
- Merck & Co.
- InterMune, Inc.
- Galectin Therapeutics, Inc.
- ProMetic Life-Sciences Inc.
- Genzyme Corporation
- BioLine Rx Ltd
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!